Castle Biosciences (CSTL) Cash & Current Investments (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Cash & Current Investments data on file, last reported at $261.7 million in Q1 2026.

• Quarterly Cash & Current Investments fell 4.89% year-over-year to $261.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $261.7 million (down 4.89% YoY) and the FY2025 annual result came in at $299.5 million, up 2.17% from the prior year.
• Cash & Current Investments eased to $261.7 million in Q1 2026 per CSTL's latest filing, from $299.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $309.0 million in Q1 2022, with the low at $225.5 million in Q2 2023.
• Average Cash & Current Investments over 5 years is $265.2 million, with a median of $266.0 million recorded in 2022.
• Year-over-year, Cash & Current Investments slipped 26.76% in 2022 and increased 21.8% in 2024.
• Castle Biosciences' Cash & Current Investments stood at $258.6 million in 2022, then slipped by 6.0% to $243.1 million in 2023, then grew by 20.58% to $293.1 million in 2024, then advanced by 2.17% to $299.5 million in 2025, then declined by 12.62% to $261.7 million in 2026.
• Business Quant data shows CSTL's Cash & Current Investments at $261.7 million in Q1 2026, $299.5 million in Q4 2025, and $287.6 million in Q3 2025.